OTTAWA,
ON, May 30, 2022 /CNW/ - Tetra
Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB:
TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery
and development is pleased to announce the appointment of
Leslie Auld, H.BSc, MBA, CPA, as
Chief Financial Officer and member of the Company's executive team,
effective May 30, 2022.
Ms. Auld is a seasoned Financial Executive with over 30 years of
relevant experience, including a background in Canadian and U.S.
publicly listed companies in the pharmaceutical and diagnostic
technology industries. She has held executive positions in
biotechnology companies developing investigational new drugs, which
is the core activity of Tetra.
Ms. Auld is an analytical, strategic, and solutions-oriented
finance professional who combines strong planning, organizational,
and communication skills with proven ability to lead high-level
operations and interact with senior management and Board of
Directors.
"We were very fortunate to find a CFO with experience in
Canadian TSX-listed biotechnology companies. Leslie has all the
skills needed to bring Tetra to its next phase of growth. I look
forward to working with Leslie through these difficult market
conditions to build Tetra into a successful pharmaceutical
company," said Dr. Chamberland, CEO.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is
a leader in cannabinoid-derived drug discovery and development with
a FDA and a Health Canada cleared clinical program aimed at
bringing novel prescription drugs and treatments to patients and
their healthcare providers. Their evidence-based scientific
approach has enabled them to develop a pipeline of
cannabinoid-based drug products for a range of medical conditions,
including pain, inflammation, and oncology. With patients at the
core of what they do, Tetra Bio-Pharma is focused on providing
rigorous scientific validation and safety data required for
inclusion into the existing biopharma industry by regulators,
physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking
statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of this
product or any other product, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-appoints-chief-financial-officer-301557276.html
SOURCE Tetra Bio-Pharma Inc.